A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

J. Mateo, D. Chakravarty, R. Dienstmann, S. Jezdic, A. Gonzalez-Perez, N. Lopez-Bigas, C. K.Y. Ng, P. L. Bedard, G. Tortora, J. Y. Douillard, E. M. Van Allen, N. Schultz, C. Swanton, F. André, L. Pusztai

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background In order to facilitate implementation of precision medicine in clinical management of cancer, there is a need to harmonise and standardise the reporting and interpretation of clinically relevant genomics data. Methods The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to propose a classification system for molecular aberrations based on the evidence available supporting their value as clinical targets. A group of experts from several institutions was assembled to review available evidence, reach a consensus on grading criteria and present a classification system. This was then reviewed, amended and finally approved by the ESMO TR and PM WG and the ESMO leadership. Results This first version of the ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines six levels of clinical evidence for molecular targets according to the implications for patient management: tier I, targets ready for implementation in routine clinical decisions; tier II, investigational targets that likely define a patient population that benefits from a targeted drug but additional data are needed; tier III, clinical benefit previously demonstrated in other tumour types or for similar molecular targets; tier IV, preclinical evidence of actionability; tier V, evidence supporting co-targeting approaches; and tier X, lack of evidence for actionability. Conclusions The ESCAT defines clinical evidence-based criteria to prioritise genomic alterations as markers to select patients for targeted therapies. This classification system aims to offer a common language for all the relevant stakeholders in cancer medicine and drug development.

Original languageEnglish
Pages (from-to)1895-1902
Number of pages8
JournalAnnals of Oncology
Volume29
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Precision Medicine
Medical Oncology
Translational Medical Research
Neoplasms
Genomics
Pharmaceutical Preparations
Consensus
Language
Medicine
Population
Therapeutics

Keywords

  • biomarkers
  • classification system
  • genomics
  • next-generation sequencing
  • precision medicine
  • targeted therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., Gonzalez-Perez, A., Lopez-Bigas, N., ... Pusztai, L. (2018). A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 29(9), 1895-1902. https://doi.org/10.1093/annonc/mdy263

A framework to rank genomic alterations as targets for cancer precision medicine : The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). / Mateo, J.; Chakravarty, D.; Dienstmann, R.; Jezdic, S.; Gonzalez-Perez, A.; Lopez-Bigas, N.; Ng, C. K.Y.; Bedard, P. L.; Tortora, G.; Douillard, J. Y.; Van Allen, E. M.; Schultz, N.; Swanton, C.; André, F.; Pusztai, L.

In: Annals of Oncology, Vol. 29, No. 9, 01.09.2018, p. 1895-1902.

Research output: Contribution to journalArticle

Mateo, J, Chakravarty, D, Dienstmann, R, Jezdic, S, Gonzalez-Perez, A, Lopez-Bigas, N, Ng, CKY, Bedard, PL, Tortora, G, Douillard, JY, Van Allen, EM, Schultz, N, Swanton, C, André, F & Pusztai, L 2018, 'A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)', Annals of Oncology, vol. 29, no. 9, pp. 1895-1902. https://doi.org/10.1093/annonc/mdy263
Mateo, J. ; Chakravarty, D. ; Dienstmann, R. ; Jezdic, S. ; Gonzalez-Perez, A. ; Lopez-Bigas, N. ; Ng, C. K.Y. ; Bedard, P. L. ; Tortora, G. ; Douillard, J. Y. ; Van Allen, E. M. ; Schultz, N. ; Swanton, C. ; André, F. ; Pusztai, L. / A framework to rank genomic alterations as targets for cancer precision medicine : The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). In: Annals of Oncology. 2018 ; Vol. 29, No. 9. pp. 1895-1902.
@article{b4498c86b95f42908e0b7ff1eb09a503,
title = "A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)",
abstract = "Background In order to facilitate implementation of precision medicine in clinical management of cancer, there is a need to harmonise and standardise the reporting and interpretation of clinically relevant genomics data. Methods The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to propose a classification system for molecular aberrations based on the evidence available supporting their value as clinical targets. A group of experts from several institutions was assembled to review available evidence, reach a consensus on grading criteria and present a classification system. This was then reviewed, amended and finally approved by the ESMO TR and PM WG and the ESMO leadership. Results This first version of the ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines six levels of clinical evidence for molecular targets according to the implications for patient management: tier I, targets ready for implementation in routine clinical decisions; tier II, investigational targets that likely define a patient population that benefits from a targeted drug but additional data are needed; tier III, clinical benefit previously demonstrated in other tumour types or for similar molecular targets; tier IV, preclinical evidence of actionability; tier V, evidence supporting co-targeting approaches; and tier X, lack of evidence for actionability. Conclusions The ESCAT defines clinical evidence-based criteria to prioritise genomic alterations as markers to select patients for targeted therapies. This classification system aims to offer a common language for all the relevant stakeholders in cancer medicine and drug development.",
keywords = "biomarkers, classification system, genomics, next-generation sequencing, precision medicine, targeted therapies",
author = "J. Mateo and D. Chakravarty and R. Dienstmann and S. Jezdic and A. Gonzalez-Perez and N. Lopez-Bigas and Ng, {C. K.Y.} and Bedard, {P. L.} and G. Tortora and Douillard, {J. Y.} and {Van Allen}, {E. M.} and N. Schultz and C. Swanton and F. Andr{\'e} and L. Pusztai",
year = "2018",
month = "9",
day = "1",
doi = "10.1093/annonc/mdy263",
language = "English",
volume = "29",
pages = "1895--1902",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "9",

}

TY - JOUR

T1 - A framework to rank genomic alterations as targets for cancer precision medicine

T2 - The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

AU - Mateo, J.

AU - Chakravarty, D.

AU - Dienstmann, R.

AU - Jezdic, S.

AU - Gonzalez-Perez, A.

AU - Lopez-Bigas, N.

AU - Ng, C. K.Y.

AU - Bedard, P. L.

AU - Tortora, G.

AU - Douillard, J. Y.

AU - Van Allen, E. M.

AU - Schultz, N.

AU - Swanton, C.

AU - André, F.

AU - Pusztai, L.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background In order to facilitate implementation of precision medicine in clinical management of cancer, there is a need to harmonise and standardise the reporting and interpretation of clinically relevant genomics data. Methods The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to propose a classification system for molecular aberrations based on the evidence available supporting their value as clinical targets. A group of experts from several institutions was assembled to review available evidence, reach a consensus on grading criteria and present a classification system. This was then reviewed, amended and finally approved by the ESMO TR and PM WG and the ESMO leadership. Results This first version of the ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines six levels of clinical evidence for molecular targets according to the implications for patient management: tier I, targets ready for implementation in routine clinical decisions; tier II, investigational targets that likely define a patient population that benefits from a targeted drug but additional data are needed; tier III, clinical benefit previously demonstrated in other tumour types or for similar molecular targets; tier IV, preclinical evidence of actionability; tier V, evidence supporting co-targeting approaches; and tier X, lack of evidence for actionability. Conclusions The ESCAT defines clinical evidence-based criteria to prioritise genomic alterations as markers to select patients for targeted therapies. This classification system aims to offer a common language for all the relevant stakeholders in cancer medicine and drug development.

AB - Background In order to facilitate implementation of precision medicine in clinical management of cancer, there is a need to harmonise and standardise the reporting and interpretation of clinically relevant genomics data. Methods The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to propose a classification system for molecular aberrations based on the evidence available supporting their value as clinical targets. A group of experts from several institutions was assembled to review available evidence, reach a consensus on grading criteria and present a classification system. This was then reviewed, amended and finally approved by the ESMO TR and PM WG and the ESMO leadership. Results This first version of the ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines six levels of clinical evidence for molecular targets according to the implications for patient management: tier I, targets ready for implementation in routine clinical decisions; tier II, investigational targets that likely define a patient population that benefits from a targeted drug but additional data are needed; tier III, clinical benefit previously demonstrated in other tumour types or for similar molecular targets; tier IV, preclinical evidence of actionability; tier V, evidence supporting co-targeting approaches; and tier X, lack of evidence for actionability. Conclusions The ESCAT defines clinical evidence-based criteria to prioritise genomic alterations as markers to select patients for targeted therapies. This classification system aims to offer a common language for all the relevant stakeholders in cancer medicine and drug development.

KW - biomarkers

KW - classification system

KW - genomics

KW - next-generation sequencing

KW - precision medicine

KW - targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=85054325308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054325308&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy263

DO - 10.1093/annonc/mdy263

M3 - Article

C2 - 30137196

AN - SCOPUS:85054325308

VL - 29

SP - 1895

EP - 1902

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -